View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 19, 2021

Bold Therapeutics’ oncology agent effective against Covid-19 variants

Bold Therapeutics has reported that its first-in-class oncology and antiviral therapeutic, BOLD-100, consistently reduced viral concentrations in several variants of Covid-19, including the B.1.1.7 variant originally identified in the UK.

Bold Therapeutics has reported that its first-in-class oncology and antiviral therapeutic, BOLD-100, consistently reduced viral concentrations in several variants of Covid-19, including the B.1.1.7 variant originally identified in the UK.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The company announced the robust preclinical efficacy data of BOLD-100 in a new in vitro research completed by collaborators at the University of British Columbia and Western University.

The latest work expands upon previous research demonstrating that the antiviral therapeutic has strong antiviral activity against the disease in a range of preclinical in vitro models.

To enhance outcomes in Covid-19 patients, Bold Therapeutics continues to advance BOLD-100 as a versatile therapeutic.

Bold Therapeutics noted that the broad antiviral mechanism-of-action of BOLD-100 appears to be unaffected by viral mutations.

It is capable of selectively inhibiting stress-induced upregulation of master chaperone protein GRP78 which plays a vital role in replication of virus.

More than 200 academic articles have identified GRP78 as a potentially attractive antiviral target.

The company, which has generated additional efficacy and safety data, is currently completing in vivo studies of BOLD-100.

It also continues to enrol patients in its Phase Ib study of the antiviral therapeutic for treating advanced gastrointestinal cancers.

More than 50 cancer patients received treatment with BOLD-100, suggesting that it is generally safe and well-tolerated. It is a clinical-stage product and has regulatory clearance in both Canada and the US to initiate clinical trials.

In December 2020, National Research Council of Canada Industrial Research Assistance Program selected Bold Therapeutics for Covid-19 funding and support.

Other companies that received the funding are JN Nova Pharma, Laurent Pharmaceuticals, and Qu Biologics.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena